Trouver un essai clinique - Global

Trouver un essai clinique

Ipsen mène des essais cliniques pour faire avancer la science et apporter de nouvelles options innovantes aux patients

Icône d'alerte

La liste ci-dessous contient des informations sur les essais cliniques financés par Ipsen.

Seules les études interventionnelles qui ont débuté au cours des 20 dernières années et se sont achevées au cours des 2 dernières années seront affichées.

Les résultats de l’étude seront disponibles sur ClinicalTrials.gov à partir de 12 mois après la fin de l’étude.

Last Data Refreshed @ 15-May-2025 16:08:09 UTC

Filtres

Condition

Statut

Phase

Country

Showing : 15 de 163 clinical trials

Upper Limb Spasticity

Dysport

AustraliaAustralia


Not Yet Recruiting

Not Yet Recruiting

Dummy study Ipsen.com 2025 with only EUDRACT

This is a test
1. line break
2. line break

Upper Limb Spasticity

Dysport

AustriaAustria


Not Yet Recruiting

Not Yet Recruiting

Dummy study Ipsen.com 2025 with only EUCT

This is a test
1. line break
2. line break

Fibrodysplasia Ossificans Progressiva (FOP)

Sohonos

United States of America (the)United States of America (the)

United Kingdom of Great Britain and Northern Ireland (the)United Kingdom of Great Britain and Northern Ireland (the)

BrazilBrazil

FranceFrance

CanadaCanada

AustraliaAustralia

ArgentinaArgentina

ItalyItaly

SpainSpain

SwedenSweden


Not Yet Recruiting

Not Yet Recruiting

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ?14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.

The main objective of this study is to further evaluate the safety and efficacy of palovarotene in adult and paediatric participants with FOP. The aim of the study is also to ensure treatment continuity to participants who have completed one of the parent studies (Study PVO-1A-301, Study PVO-1A-202 and Study PVO-1A-204) and who, in the investigator’s judgement, may benefit from palovarotene therapy.

Indication Study X1

elafibranor

United States of America (the)United States of America (the)

United Kingdom of Great Britain and Northern Ireland (the)United Kingdom of Great Britain and Northern Ireland (the)

ItalyItaly

FranceFrance

GabonGabon


Not Yet Recruiting

Not Yet Recruiting

Indication Study X1

elafibranor

United Kingdom of Great Britain and Northern Ireland (the)United Kingdom of Great Britain and Northern Ireland (the)

United States of America (the)United States of America (the)

GabonGabon

FranceFrance

ItalyItaly


Not Yet Recruiting

Not Yet Recruiting